Brain Imaging Biomarkers for Brain Metastases

Overseen By Catherine Coolens, Ph. D

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: University Health Network, Toronto

Disqualifiers: Previous radiotherapy, Radiosurgery, MRI inability

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 5

90 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if certain brain imaging markers can predict how well patients with brain metastases respond to radiation treatment. Participants will undergo CT and MRI scans before and after their radiation therapy to assess if these scans can help doctors understand the treatment's effects. This study suits individuals with brain metastases scheduled for radiation therapy, particularly those with a tumor larger than 1 cm without bleeding. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in cancer treatment.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that CT and MRI scans are safe for brain metastases patients?

Studies have shown that both CT and MRI scans are generally safe, but each carries its own risks. CT scans use radiation, and some research suggests frequent use might slightly increase cancer risk. However, the radiation from a single head CT scan remains relatively low, at about 50 to 60 mGy.

MRI scans do not use radiation, making them safer in that regard. However, the strong magnets in MRIs can affect metal in the body, such as pacemakers or metal implants. Informing a doctor about any metal in the body before an MRI is crucial.

Overall, these imaging techniques are well-tolerated and widely used in medical settings. Discuss any concerns with a healthcare provider. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the use of CT and MRI scans for brain metastases because these imaging techniques might offer precise insights into how tumors respond to treatment. Unlike standard treatments that focus directly on attacking the cancer cells, this approach aims to enhance our understanding of tumor behavior and treatment effectiveness through advanced imaging. The use of dynamic contrast-enhanced scans provides detailed information about blood flow and tissue structure, potentially leading to more tailored and effective treatment plans for patients.

What evidence suggests that CT and MRI scans are effective for predicting responses to radiation treatment in brain metastases?

In this trial, participants will undergo both MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans to assess brain metastases. Studies have shown that MRI is crucial for examining brain tumors, including those that have spread from other parts of the body, as it provides clear images of the brain, aiding in diagnosis and management. When combined with CT scans, even more detailed information about the brain's structure emerges. These imaging techniques are important because they can indicate the severity or presence of a disease. Research indicates that these scans can help predict how well patients with brain metastases will respond to radiation treatment. Overall, evidence supports using CT and MRI scans as effective tools for assessing and managing brain metastases. ^{1 6 7 8 9}

Who Is on the Research Team?

Catherine Coolens, Ph. D

Principal Investigator

Princess Margaret Cancer Center - UHN

Are You a Good Fit for This Trial?

This trial is for adults over 18 with confirmed primary cancer and brain metastases visible on scans, who are scheduled for radiation therapy. They must have at least one lesion larger than 1cm without bleeding in the brain and be able to consent. Those with prior whole-brain radiotherapy or radiosurgery to the target lesion, or unable to have contrasted MRI cannot join.

Inclusion Criteria

I have a tumor larger than 1cm without any bleeding inside it.

I am older than 18 years.

My cancer diagnosis was confirmed with a biopsy, and I have brain metastases.

Exclusion Criteria

I have had radiosurgery on the main tumor.

I have had whole brain radiotherapy before.

You cannot have a MRI scan with contrast dye for any reason.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1 week

1 visit (in-person)

Radiation Treatment

Participants receive radiation treatment for brain metastases

Duration not specified

1 visit (in-person)

Imaging and Biomarker Assessment

CT and MRI scans are conducted prior to and after radiation treatment to measure biomarkers

3 months

3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 2 years

Routine follow-up visits as per standard of care

What Are the Treatments Tested in This Trial?

Interventions

• CT and MRI Scans

Trial Overview The study tests if CT and MRI scans before and after radiation can act as biomarkers—signs that show how severe a disease is or if it's present—to predict treatment response in patients with brain tumors from metastasized cancer.

How Is the Trial Designed?

Group I: CT and MRI Scans Experimental Treatment 1 Intervention

Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials

1,555

Recruited

526,000+

Published Research Related to This Trial

Advanced magnetic resonance imaging (MRI) techniques can provide quantitative parameters that help in diagnosing and managing cerebral metastases, improving the accuracy of distinguishing these from primary brain tumors and other mimics.

These imaging biomarkers may also assist in predicting the origin of the primary tumor, which is crucial for effective treatment planning.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Advanced magnetic resonance imaging biomarkers of cerebral metastases. Mills, SJ., Thompson, G., Jackson, A.[2021]

MRI is generally safe for humans, even with repeated exposure, but certain components can cause temporary inconveniences or severe accidents if safety protocols are not followed.

The article reviews reported MRI accidents, explaining their mechanisms and emphasizing the importance of strict safety measures to prevent serious adverse effects, including potential fatalities.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Risks associated with MRI: safety rules, incidents, and accidents]. de Kerviler, E., de Bazelaire, C., Mathieu, O., et al.[2019]

MRI showed a higher tendency for preoperative detection of brain metastases compared to CT, identifying 3.4% of patients versus 0.6% for CT, suggesting MRI may be more effective for early detection in lung cancer patients.

Despite MRI detecting smaller brain metastases (average diameter of 12.8 mm) compared to CT (20.3 mm), there was no significant difference in survival rates between the two imaging methods, indicating that early detection does not necessarily translate to improved survival outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Yokoi, K., Kamiya, N., Matsuguma, H., et al.[2022]

In a study involving 148,489 patients over 10 years, gadoteric acid (Dotarem®) was found to be a safe MRI contrast agent, with only 0.3% of patients experiencing adverse events, primarily mild symptoms like nausea and vomiting.

The diagnostic effectiveness was high, with 99.8% of examinations yielding useful results and excellent or good image quality in 97.7% of cases, indicating that gadoteric acid is effective for routine MRI procedures.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients. Braun, J., Busse, R., Darmon-Kern, E., et al.[2020]

MRI is essential for evaluating brain masses, but challenges remain in accurately detecting and diagnosing brain metastases, particularly in distinguishing them from primary tumors and infections.

Newer MRI techniques and PET imaging are being investigated to improve the detection and characterization of brain metastases, offering valuable insights into tumor biology that could enhance patient management and treatment response monitoring.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Brain metastases: neuroimaging. Pope, WB.[2018]

Functional neuroimaging techniques like MRI and PET are becoming crucial for diagnosing brain metastases, monitoring treatment responses, and predicting patient prognosis.

As cancer therapies improve and patients live longer, these advanced imaging methods help in better detecting brain tumors and assessing the effectiveness of new targeted and immunomodulatory treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The emerging role of advanced neuroimaging techniques for brain metastases. Nowosielski, M., Radbruch, A.[2015]

Neuroimaging, particularly computed tomography and magnetic resonance imaging, is essential for diagnosing and differentiating brain metastases in patients with known or unknown cancers, helping to identify solitary brain lesions effectively.

Advanced imaging techniques and the integration of artificial intelligence enhance the accuracy of diagnosis and treatment assessment, allowing for better differentiation between tumor recurrence and treatment-related complications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Morphological and Functional Neuroradiology of Brain Metastases. Grazzini, I., Venezia, D., Del Roscio, D., et al.[2023]

Magnetic resonance imaging (MRI) is generally considered both safe and effective for diagnostic purposes, with ongoing improvements in technology and clinical practices enhancing its safety profile.

The article reviews various safety considerations related to MRI operations, highlighting the importance of understanding both bioeffects and operational safety issues based on extensive clinical experience and reported incidents.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Operational safety issues in MRI. Gangarosa, RE., Minnis, JE., Nobbe, J., et al.[2019]

Multimodal MRI significantly improves the accuracy of tumor delineation in brain metastases compared to single-modality imaging, with a more precise measurement of tumor volume (132 ± 41 μL vs. 85 ± 36 μL from single-modality MRI).

The use of multimodal MRI enhances sensitivity for detecting metastases (0.82 vs. 0.61 for single-modality), which could lead to better treatment planning and potentially reduce relapse rates and improve survival in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Improving Delineation of True Tumor Volume With Multimodal MRI in a Rat Model of Brain Metastasis. Larkin, JR., Simard, MA., de Bernardi, A., et al.[2021]

Screening MRI scans can help detect brain metastases early in patients with metastatic melanoma, identifying 39% of cases, including 8 asymptomatic patients, which can lead to timely treatment decisions.

Follow-up MRI scans significantly influenced treatment strategies in 45% of cases for patients with melanoma brain metastases, although fewer changes were noted in patients who had been on immune checkpoint inhibitors for a longer duration.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. Eggen, AC., Wind, TT., Bosma, I., et al.[2022]

The study successfully established a VX2 rabbit model for brain metastases, demonstrating its feasibility and safety, as no rabbits died during the procedures and they regained lost weight within 14 days.

Dynamic contrast-enhanced MRI (DCE-MRI) significantly improved the detection of brain metastases, achieving a 100% detection rate compared to only 12% and 32% for T1-weighted and T2-weighted images, respectively.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Functional dynamic contrast-enhanced magnetic resonance imaging in an animal model of brain metastases: a pilot study. Zheng, L., Sun, P., Zheng, S., et al.[2021]

Brain metastases are the most common type of intracranial tumors, affecting 20-40% of cancer patients, with lung cancer, breast cancer, and melanoma being the primary sources.

Advanced MRI techniques, such as magnetic resonance spectroscopy and diffusion-based imaging, can enhance the detection and management of brain metastases by providing detailed insights into tumor characteristics and treatment responses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Advanced Magnetic Resonance Imaging Techniques in Management of Brain Metastases. Mehrabian, H., Detsky, J., Soliman, H., et al.[2020]

Using automated color-coding for assessing brain metastases significantly improved the accuracy of diagnoses, with a correct classification rate of 91.3% compared to 74.0% with conventional methods, based on a study of 121 pairs of follow-up MR examinations.

The use of automated color-coding also enhanced radiologists' diagnostic certainty, as indicated by an increase in the median Likert score from 2 to 4, although it required more time for image processing compared to traditional reading.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Automated Color-Coding of Lesion Changes in Contrast-Enhanced 3D T1-Weighted Sequences for MRI Follow-up of Brain Metastases. Zopfs, D., Laukamp, K., Reimer, R., et al.[2023]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC6118134/

Brain metastases: neuroimaging - PMC - PubMed Central This chapter reviews standard and advanced imaging of brain metastases provided by computed tomography, MRI, and amino acid PET, focusing on potential ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC3458786/

Advanced magnetic resonance imaging biomarkers of ... This article reviews the magnetic resonance imaging (MRI) techniques available for use in the diagnosis and management of patients with cerebral metastases.

3. nature.com nature.com/articles/s41698-024-00789-2

A review of deep learning for brain tumor analysis in MRI This review explores the transformative impact of DL on brain tumor analysis, focusing on its applications in two broad areas: segmentation and classification.

4. sciencedirect.com sciencedirect.com/science/article/abs/pii/B9780128111611000074

Brain metastases: neuroimaging Magnetic resonance imaging (MRI) is the cornerstone for evaluating patients with brain masses such as primary and metastatic tumors.

5. withpower.com withpower.com/trial/phase-3-brain-neoplasms-5-2021-1f7a8

Brain Imaging Biomarkers for Brain Metastases Trial Overview The study tests if CT and MRI scans before and after radiation can act as biomarkers—signs that show how severe a disease is or if it's present— ...

6. cancer.gov cancer.gov/about-cancer/diagnosis-staging/ct-scans-fact-sheet

Computed Tomography (CT) Scans and Cancer Fact Sheet A fact sheet that describes the CT scan procedure and technology and its uses in screening, diagnosis, and treatment.

7. mayoclinicproceedings.org mayoclinicproceedings.org/article/s0025-6196(15)00591-1/fulltext

Answers to Common Questions About the Use and Safety ... For reference the brain dose from a head CT scan is approximately 50 to 60 mGy and the colon dose from an abdomen/pelvis CT scan is approximately 15 to 20 mGy.

8. ucsf.edu ucsf.edu/news/2025/04/429791/popular-ct-scans-could-account-5-all-cancer-cases-year

Popular CT Scans Could Account for 5% of All Cancer ... CT scans may account for 5% of all cancers annually, according to a new study that cautions against overusing and overdosing CTs.

9. emedicine.medscape.com emedicine.medscape.com/article/338239-overview

Brain Metastasis Imaging On noncontrast computed tomography (CT), the density of metastatic lesions may be less than, equal to, or greater than that of adjacent brain ...